Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Ka inhibitor alpelisib in HER2+ PIK3CA-mutated metastatic breast cancer

Document Type

Conference Proceeding

Publication Date

5-29-2024

Publication Title

Journal of Clinical Oncology

Abstract

Annual Meeting of the American Society of Clinical Oncology, ASCO 2024; May 31 - June 4, 2024; Chicago, IL

Volume

42

Issue

16

Comments

Abstract e13021

Share

COinS